Bausch + Lomb Corp.
BLCO
19.38
-1.31
-6.33%
Bausch + Lomb Corp.
US · BLCO
#1909 by market cap
Listed 2022
19.38
-1.31
-6.33%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.9 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 97.59% -1.86pp
- Institutions
- 116 +5
- As of
- 2026/Q3 vs. prior period
Holder types
Public Company88.25%
Hedge Fund4.82%
Mutual Fund1.93%
Family Office/Trust1.23%
VC/PE Fund1.12%
Private Company0.23%
Individual/Insider0.18%
Other2.23%
Top holders as of 2025-12-09
Bausch Health Companies Inc.
86.84% · 310.45M sh
Icahn Capital LP
0.98% · 3.50M sh
Brookfield Corporation
0.96% · 3.44M sh
Deutsche Bank Aktiengesellschaft
0.93% · 3.33M sh
D. E. Shaw & Co., L.P.
0.93% · 3.32M sh
Davidson Kempner Capital Management LP
0.88% · 3.16M sh
GoldenTree Asset Management LP
0.74% · 2.66M sh
T. Rowe Price Group, Inc.
0.60% · 2.16M sh
Glenview Capital Management, LLC
0.54% · 1.92M sh
Arrowstreet Capital, Limited Partnership
0.38% · 1.36M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 31 buys · 18 sells
| Name | Role | Stake |
|---|---|---|
| Bausch Health Companies Inc. | -- | 86.84% |
| Brenton Saunders | Chairperson & CEO | 0.12% |
| Osama Eldessouky | Chief Financial Officer | 0.06% |
| A. Robert Bailey | Chief Legal Officer | 0.04% |
| Yehia Hashad | Executive VP of Research & Development and Chief Medical officer | 0.03% |
| Andrew von Eschenbach | Former Independent Director | 0.01% |
| Luc Bonnefoy | President of Surgical | 0.01% |
| Richard De Schutter | Former Independent Director | 0.01% |
| Andrew Stewart | President of Global Pharmaceuticals & International Consumer | 0.01% |
| Thomas Appio | Interim CEO & Chairman of the Board | 0.01% |
| John Paulson | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-11 | Karen Ling | Former Independent Director | Intent to Sell (Form 144) | -12,838 | $21.01 |
| 2026-11-02 | Nathalie Bernier | Former Independent Director | Intent to Sell (Form 144) | -40,022 | $19.88 |
| 2026-10-28 | John Paulson | Independent Director | Other Acquisition | +1,125 | $20.40 |
| 2026-10-28 | Russel Robertson | Independent Director | Other Acquisition | +1,256 | $20.40 |
| 2026-10-28 | Eduardo Alfonso | Independent Director | Other Acquisition | +1,125 | $20.40 |
| 2026-10-28 | Frederick Munsch | Chief Accounting Officer | Derivative Exercise and Sale | -112,015 | $17.96–20.48 |
| 2026-09-27 | Karen Ling | Former Independent Director | Intent to Sell (Form 144) | -4,500 | $16.83 |
| 2026-08-11 | Laurence Paul | Lead Independent Director | Other Acquisition | +11,776 | -- |
| 2026-08-11 | Robert Chersi | Director | Other Acquisition | +11,776 | -- |
| 2026-08-11 | Barbara Trebbi | Director | Other Acquisition | +11,776 | -- |
| 2026-08-09 | Frederick Munsch | Chief Accounting Officer | Open Market Disposition | -52,900 | $16.78 |
| 2026-08-09 | Frederick Munsch | Chief Accounting Officer | Intent to Sell (Form 144) | -52,900 | $16.78 |
| 2026-08-06 | Andrew von Eschenbach | Former Independent Director | Open Market Disposition | -18,559 | $16.50–16.58 |
| 2026-08-06 | Andrew von Eschenbach | Former Independent Director | Intent to Sell (Form 144) | -6,059 | $16.58 |
| 2026-08-05 | Andrew von Eschenbach | Former Independent Director | Intent to Sell (Form 144) | -12,500 | $16.50 |
| 2026-08-04 | Brenton Saunders | Former Chief Executive Officer | Sale to Issuer | -4,231 | $16.76 |
| 2026-08-04 | Brenton Saunders | Former Chief Executive Officer | Other Acquisition | +281,879 | -- |
| 2026-08-04 | Thomas Appio | Interim CEO & Chairman of the Board | Initial Statement of Beneficial | 0 | -- |
| 2026-08-04 | A. Robert Bailey | Chief Legal Officer | Other Acquisition | +33,557 | -- |
| 2026-08-04 | Osama Eldessouky | Chief Financial Officer | Other Acquisition | +50,335 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Bausch + Lomb Corp. discussion 0 comments